ReviewThe oncologist2026
Bone health in advanced prostate cancer: pathophysiology and management strategies.
Review in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Bone loss and bone metastases can increase morbidity and impair quality of life for patients with prostate cancer. Use of hormonal agents can compromise bone integrity from treatment initiation, and the emergence of bone metastases further increases the risk of symptomatic skeletal-related events. Management of bone health should therefore be pivotal across the prostate cancer continuum. Current guidelines recommend that all men starting or receiving androgen-deprivation therapy for prostate cancer be assessed regularly for bone loss using predictive tools such as dual-energy X-ray absorptiometry and Trabecular Bone Score. Bone health agents (BHAs) are recommended for all men with castration-resistant prostate cancer with skeletal metastases to prevent symptomatic skeletal-related events and for high-risk men receiving androgen-deprivation therapy to prevent treatment-related bone loss. Options include bisphosphonates such as zoledronic acid and alendronate and the receptor activator of nuclear factor kappa-B ligand inhibitor denosumab. Patients should be monitored for adverse effects of BHAs, such as osteonecrosis of the jaw and hypocalcemia. Alongside BHAs, there are treatment options for metastatic castration-resistant prostate cancer associated with beneficial bone-related effects, notably abiraterone acetate, enzalutamide, and radium-223. In this narrative review, we focus on how bone health management can be integrated into standard clinical practice in men with advanced prostate cancer. We also present a test-and-treatment algorithm for bone health management in men with metastatic prostate cancer. Improving treatment-related bone loss and proactively managing bone metastases should be standard practice in all men with prostate cancer to improve health outcomes and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.